Brian Elsbernd - 14 Feb 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role: Chief Compliance/Legal Officer
Signature: /s/ Brian Elsbernd
Issuer symbol: CPRX
Transactions as of: 14 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 19 Feb 2025, 17:00:18 UTC
Previous filing: 31 Dec 2024
Next filing: 05 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CPRX	Common Stock, par value $0.001 per share	Options Exercise		+9,667	+5.3%		190,917	14 Feb 2025	Direct	F1
transaction	CPRX	Common Stock, par value $0.001 per share	Tax liability		-2,353	-1.2%		188,564	14 Feb 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CPRX	Restricted Stock Units	Options Exercise	$0	-9,667	-0.89%	$0.000000	1,071,609	14 Feb 2025	Common Stock	9,667		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2	Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3	Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4	Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025.